Precision Medicine
-
Approach to Management of ROS1m NSCLC
Charu Aggarwal, MD, MPH
-
Integrating NORTHSTAR/COMPEL Into Clinical Practice: A Tumor Board Focused on Duration of Osimertinib Therapy
Zofia Piotrowska, MD, MHS; Charu Aggarwal, MD, MPH
-
Post ASCO Update on Management of HER2+ Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
Tanios S. Bekaii-Saab, MD
-
ASCO Update: Daraxonrasib (RMC-6236) for KRAS mutated metastatic pancreatic cancer
John Strickler, MD; Tanios S. Bekaii-Saab, MD
-
An Update on the role of ctDNA-MRD Assessment in The Management of Breast Cancer
Jason A. Mouabbi, MD
-
Importance of NGS testing for STK11 and KEAP1 mutation and impact on treatment selection
Charu Aggarwal, MD, MPH; Biagio Ricciuti, MD, PhD
-
Advancements in the Treatment of Early Stage Gastroesophageal Adenocarcinoma
Tanios S. Bekaii-Saab, MD
-
Multidisciplinary Tumor Board: Focus on Early-Stage KRAS Mutated NSCLC
Brendon Stiles, MD; Charu Aggarwal, MD, MPH
